Many studies carried out in the 1990s and early 2000s demonstrated that tumors or tumor cell lines engineered to produce IL-4 would exhibit increased rejection and retarded growth in vivo; curiously a phenotype often dependent on CD8+ cytotoxic T cells (160–163). The gene discussed is CD8A; the disease is neoplasm.